Ascendis Pharma A/S

Ascendis Pharma A/S's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Ascendis Pharma A/S has 65.67M shares outstanding.

As of June 30, 2026, Ascendis Pharma A/S maintains a current ratio of 2.99, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.33, indicating elevated leverage, while an interest coverage ratio of 2.33 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) stands at 43.97, measuring how efficiently the asset base is converted into earnings. Inventory turnover of 0.30 indicates how many times Ascendis Pharma A/S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ascendis Pharma A/S recorded an income tax benefit of -12.85B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 1.95B, leaving 14.81B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Ascendis Pharma A/S generated 20.90B in revenue and converted that into 14.81B in net income, yielding earnings per share of 232.60. EBITDA reached 5.66B, while operating income came in at 5.24B.

As of June 30, 2026, Ascendis Pharma A/S holds 16.21B in cash and equivalents against 8.98B in total debt, resulting in a net debt position of -7.23B. Total book value stands at 28.67B, with working capital of 18.47B providing operational flexibility.

Ascendis Pharma A/S produced 6.98B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -68.74M in capital expenditures, free cash flow totaled 6.91B - equivalent to 111.50 per share.

Over the twelve months ended June 30, 2026, Ascendis Pharma A/S posted a gross margin of 91.30, reflecting its pricing power and cost economics. The operating margin of 25.09 and net profit margin of 70.84 provide insight into operational efficiency.